If you have not registered for one of our webinars in the past, please subscribe to AOAAM, then login and register for the webinars.

Hot Topics - On-Demand

16 Results

  • Q&A Session: Group Based Opioid Treatment

    Contains 3 Component(s), Includes Credits Recorded On: 04/28/2021

    ORN Webinar Series: This is a follow up Q&A Session: Group Based Opioid Treatment webinar. The webinar "Group Based Opioid Treatment" introduced a group-based format to deliver opioid use disorder (OUD) treatment incorporating medications and psychosocial programming. The number of people in need of OUD treatment continues to woefully outpace the availability of treatment providers. Providing treatment with multiple patients in a group-based setting is a strategy that can markedly expand access. Other benefits include enhancing patient recovery networks, improving provider satisfaction and financial viability. This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.

  • Group Based Opioid Treatment

    Contains 3 Component(s), Includes Credits Recorded On: 04/21/2021

    ORN Webinar Series: This webinar will introduce a group-based format to deliver opioid use disorder (OUD) treatment incorporating medications and psychosocial programming. The number of people in need of OUD treatment continues to woefully outpace the availability of treatment providers. Providing treatment with multiple patients in a group-based setting is a strategy that can markedly expand access. Other benefits include enhancing patient recovery networks, improving provider satisfaction and financial viability. This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.

  • Q&A Session: Buprenorphine Induction for High Potency Synthetic Opioid Users

    Contains 3 Component(s), Includes Credits Recorded On: 04/14/2021

    ORN Webinar Series: Q&A Session following a presentation on the use of injectable buprenophrine for the treatment of Opioid Use Disorder (OUD) in patients using Highly Potent Synthetic Opioids (HPSO). This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.

  • Buprenorphine Induction for High Potency Synthetic Opioid Users

    Contains 3 Component(s), Includes Credits Recorded On: 04/07/2021

    ORN Webinar Series: Presentation on the use of injectable buprenophrine for the treatment of Opioid Use Disorder (OUD) in patients using Highly Potent Synthetic Opioids (HPSO). This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.

  • Access to Buprenorphine Treatment for Opioid Use Disorder

    Contains 3 Component(s), Includes Credits Recorded On: 03/24/2021

    ORN Webinar Series: A lecture covering the current landscape of buprenorphine treatment availability and ongoing issues is making this medication available, accessible and sustainable for all in need. This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.

  • Q&A Session: Treatment of Perinatal Opioid Use Disorder via Telemedicine

    Contains 3 Component(s) Recorded On: 11/11/2020

    This is the sixth Q & A webinar in the telehealth series for the Opioid Response Network (ORN). Post your questions at: https://docs.google.com/document/d/1jWnx8vzasVmq_zIV9nLWIRr4qYJ14oiYHYr7w2HTd1w/edit?usp=sharing Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.